Yunxin Biological Technology Co.,Ltd.
Yunxin Biological Technology Co.,Ltd. is located in the silver technology business incubator Building 2, is engaged in a pharmaceutical raw materials and intermediates research and development, production and sales integration of enterprises.The company was founded in June 2016, strong technical force. Have a sound product testing methods and quality assurance system. Companies to the world's pharmaceutical industry trends to do the wizard, closely follow the development of new drugs at home and abroad market, and constantly develop and research new products to meet the different needs of customers.Companies adhering to the "quality first, customer first" business purpose, advocate "people-oriented, realistic and innovative" corporate philosophy. And constantly strengthen the building of enterprise culture, improve their competitiveness, is committed to improving product quality and service quality, so that the new company to become fine chemical industry outstanding enterprises. We sincerely look forward to working with domestic and foreign customers work together to create a new future.The company's main products are: methotrexate, gefitinib, leucovorin, lapatinib, bosutinib, topotecan and so on.The company's main products:1, methotrexate: anti-folic acid antitumor drugs. Mainly through the inhibition of dihydrofolate reductase to achieve the inhibition of tumor cell DNA synthesis, and inhibit tumor cell growth and reproduction. Mainly used for acute leukemia, head and neck cancer, bone tumors and other types of cancer treatment. Due to broad spectrum of anti-cancer, the exact effect, has become the treatment of various types of cancer disease first-line medication.2, gefitinib: quinazoline class of anti-tumor drugs. Is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which is usually expressed in epithelial-derived solid tumors. Suitable for the treatment of locally late or metastatic non-small cell lung cancer (NSCLC) who have previously received chemotherapy or are not suitable for chemotherapy. Mainly for the treatment of non-small cell lung cancer.3, tootinib: for cancer anti-signal transduction drug. Is a small molecule protein kinase inhibitor. Mainly used in patients with moderate to severe active rheumatoid arthritis (RA) in patients with inadequate or intolerant response to methotrexate. Due to broad spectrum of anti-cancer, the exact effect, has become the treatment of various types of cancer disease first-line medication.Company's future outlook:1, in the next three years, under the leadership of the company, through the company's tireless efforts of all staff, vigorously explore the market business, and strive to achieve steady growth of corporate income.2, and gradually expand the company's production lines for the company to expand the scale to provide a solid foundation.3, innovative means of publicity, to improve customer awareness of the "new biotechnology".4, to strengthen production, improve production levels, to ensure product quality, establish a "new" brand, with high-quality products to attract customers.5, increase investment in research and development funds, increase the intensity of research and development of new products, research and development and experimental new products.We sincerely look forward to working with domestic and foreign customers work together to create "new biotechnology" new future!
Search Product